Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that targets tumors by activating antigen-presenting cells like dendritic cells (DC), initiating tumor-reactive T cells, promoting tumor-specific T cell infiltration and destruction of tumors, and remodeling the tumor-infiltrating myeloid microenvironment .

p-Hydroxy-5,6-dehydrokawain is isolated from Kawain.

Copper(II) D-gluconate powder in combination with silicon was used for the fabrication of carbon coated Si-Cu3Si composite as the anode materials for Li-ion batteries.